Mutated anti-TNFα antibodies and methods of their use
US8921526B2 · kind B2 · utility
34Cited by
116References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 12, 2014 |
| Grant date | Dec 30, 2014 |
| Priority date | — |
| Expiry date | Mar 12, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention is directed to modified antibodies, including anti-TNFα antibodies, in which C-terminal amino acids of heavy chain sequences are modified from a native sequence of proline-glycine-lysine (“PGK”) to one that includes a proline positioned between the glycine and lysine, resulting in a C-terminal sequence of proline-glycine-proline-lycine (“PGPK”). The invention further provides methods of producing and using such antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.